1-8 of 8
Lance D. Miller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade

Available to Purchase
Pierre L. Triozzi, Elizabeth R. Stirling, Qianqian Song, Brian Westwood, Mitra Kooshki, M. Elizabeth Forbes, Beth C. Holbrook, Katherine L. Cook, Martha A. Alexander-Miller, Lance D. Miller, Wei Zhang, David R. Soto-Pantoja
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1192–1202.
https://doi.org/10.1158/1078-0432.CCR-21-3114
Published: 14 March 2022
View articletitled, Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Open the PDF for Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study

Available to Purchase
Steven D. Forsythe, Richard A. Erali, Shyama Sasikumar, Preston Laney, Ethan Shelkey, Ralph D'Agostino, Jr, Lance D. Miller, Perry Shen, Edward A. Levine, Shay Soker, Konstantinos I. Votanopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5141–5150.
https://doi.org/10.1158/1078-0432.CCR-21-0982
Published: 15 September 2021
View articletitled, Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study
Open the PDF for Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Free
Timothy S. Pardee, Rebecca G. Anderson, Kristin M. Pladna, Scott Isom, Lais P. Ghiraldeli, Lance D. Miller, Jeff W. Chou, Guangxu Jin, Wei Zhang, Leslie R. Ellis, Dmitriy Berenzon, Dianna S. Howard, David D. Hurd, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (9): 2060–2073.
https://doi.org/10.1158/1078-0432.CCR-17-2282
Published: 30 April 2018
View articletitled, A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Open the PDF for A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Free
Subrata Manna, Josefine Bostner, Yang Sun, Lance D. Miller, Anya Alayev, Naomi S. Schwartz, Elin Lager, Tommy Fornander, Bo Nordenskjöld, Jane J. Yu, Olle Stål, Marina K. Holz
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1421–1431.
https://doi.org/10.1158/1078-0432.CCR-15-0857
Published: 14 March 2016
View articletitled, ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Open the PDF for ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

Free
Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (20): 5255–5264.
https://doi.org/10.1158/1078-0432.CCR-14-1019
Published: 14 October 2014
View articletitled, A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma

Free
Philippe Broët, Cyril Dalmasso, Eng Huat Tan, Marco Alifano, Shenli Zhang, Jeanie Wu, Ming Hui Lee, Jean-François Régnard, Darren Lim, Heng Nung Koong, Thirugnanam Agasthian, Lance D. Miller, Elaine Lim, Sophie Camilleri-Broët, Patrick Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3542–3550.
https://doi.org/10.1158/1078-0432.CCR-10-2185
Published: 01 June 2011
View articletitled, Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma
Open the PDF for Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma in another window
Journal Articles

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer

Free
Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaïd, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, Patricia Forgez
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (17): 4401–4410.
https://doi.org/10.1158/1078-0432.CCR-10-0659
Published: 31 August 2010
View articletitled, Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer
Open the PDF for Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor–Positive Tumors

Free
Kun Yu, Kumaresan Ganesan, Lance D. Miller, Patrick Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3288–3296.
https://doi.org/10.1158/1078-0432.CCR-05-1530
Published: 01 June 2006
View articletitled, A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor–Positive Tumors
Open the PDF for A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor–Positive Tumors in another window
Includes: Supplementary data